Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DPP-4 Inhibition With Sitagliptin and the Risk for Hypoglycaemia in the Fasting State in Subjects With Type 2 Diabetes Treated to Fasting Plasma Glucose Targets With Insulin Glargine and Metformin

NCT03359590 is registered in ClinicalTrials.gov with Profil Institut für Stoffwechselforschung GmbH as lead sponsor.

NCT NCT03359590
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03359590 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DPP-4 Inhibition With Sitagliptin and the Risk for Hypoglycaemia in the Fasting State in Subjects With Type 2 Diabetes Treated to Fasting Plasma Glucose Targets With Insulin Glargine and Metformin
Lead sponsor
Profil Institut für Stoffwechselforschung GmbH
Phase
Phase 2
Overall status
Completed
Start date
March 21, 2018
Completion date
July 17, 2019
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pharmacological action